Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.
Type:
Grant
Filed:
January 24, 2013
Date of Patent:
April 28, 2020
Assignees:
Hoffmann-La Roche Inc., Ludwig-Maximillians-Universität München
Inventors:
Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
Abstract: Embodiments of the invention include a semiconductor light emitting device with a light emitting layer disposed between an n-type region and a p-type region. The light emitting layer emits first light. The device further includes AE1-xLi2Be4O6:Eux, wherein AE=one or more of Sr, Ba, Ca, disposed in the path of the first light. The AE1-xLi2Be4O6:Eux absorbs first light and emits second light. In some embodiments, the first light and second light may be blue.
Abstract: The invention relates to an energetic active composition comprising a dihydroxylammonium salt or diammonium salt of 5,5?-bistetrazole-1,1?-diol, 5,5?-bistetrazole-1,2?-diol or 5,5?-bistetrazole-2,2?-diol or a mixture of at least two of these salts.